Clinical trials: Open Liver Resection
Liver Cancer
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1…
- Trial name
- NCT05369650
- Testing
- Lidocaine Hydrochloride, Injectable
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Hepatectomy
Hepatic and Portal Vein Transection by Vascular Stapler in Open Living Donor Hepatectomy
To enhance donor safety in living donor liver transplantation (LDLT), the use of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation has been introduced.
- Trial name
- NCT06910852
- Testing
- Vascular stapler
- Where
- Jordan
- Volunteers
- 17 people
- Sponsor
- Abdalla Bashir, MD
Resectable Simultaneous Colorectal Cancer Liver Metastasis
The Outcomes of Laparoscopic Hybrid Surgery Versus Totally Open Surgery
Simultaneous colorectal cancer liver metastasis (SCRLM) is one of the risk factors for poor prognosis in colorectal cancer. Surgical resection of primary and metastatic lesions is the first choice of treatment for patients with…
- Trial name
- NCT06550700
- Testing
- laparoscopic hybrid surgery (LHS)
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Changhai Hospital
Hepatectomy
Intravenous Lidocaine for Hepatectomy
Liver resection is increasingly performed for hepatic tumors, mainly primary liver cancers and resectable metastases, but also for some benign lesions.
- Trial name
- ILHEP (NCT07590830)
- Testing
- Standardized General Anesthesia Induction and Maintenance Protocol incorporating Intravenous Lidocaine
- Where
- 9 sites in France
- Volunteers
- 312 people
- Sponsor
- Rennes University Hospital
Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
This clinical trial compares two different kinds of surgical closing techniques, short stitch suture or traditional suture, in patients who are having liver tumor surgery.
- Conditions
- Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
- Trial name
- NCT04982653
- Testing
- Quality-of-Life Assessment, Surgical Procedure
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Liver Surgery
ORANGE SEGMENTS: Open Versus Laparoscopic Parenchymal Preserving Postero-Superior Liver Segment Resection
The international and multicentre ORANGE SEGMENTS - Trial is a prospective, double blinded, randomized controlled study comparing patients undergoing parenchymal preserving resection of postero-superior liver segments (involving…
- Trial name
- NCT03270917
- Testing
- Parenchymal preserving postero-superior liver segment resection
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 250 people
- Sponsor
- Maastricht University Medical Center
Hepatolithiasis
Robotic-Assisted Laparoscopic Versus Open Surgery for Complicated Hepatolithiasis
The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
- Trial name
- NCT03297099
- Testing
- Robot-assisted Laparoscopic operation, open surgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Southwest Hospital, China
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Hepatocellular Carcinoma, Adjuvant Therapy
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
This is An Open, Single Arm, Multicenter, Exploratory Phase II study, to evaluate the efficacy and safety of TQB2450 Plus anlotinib as adjuvant therapy in hepatocellular carcinoma(HCC) patients at high risk of recurrence after…
- Trial name
- ALTER-H006 (NCT05111366)
- Testing
- TQB2450 injection, Anlotinib hydrochloride capsules
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Xianhai Mao
Carcinoma, Hepatocellular
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) participants who are at high risk of recurrence…
- Trial name
- NCT06454578
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Cancer, Liver Metastases
Impact of Minimally Invasive and Open Liver Surgery in Different BMI-classes
Despite the worldwide increase of both obesity and use of minimally invasive liver surgery(MILS), evidence regarding the safety and eventual benefits of MILS in obese patients is scarce.
- Conditions
- Liver Cancer, Liver Metastases, Obesity
- Trial name
- MILSOBES (NCT05475054)
- Testing
- Minimally invasive liver resection
- Where
- Italy
- Volunteers
- 9,963 people
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Hepatectomy, Intertransverse Process Block
Intertransverse Process Block for Quality of Recovery Post-Open Hepatectomy
The study aims to assess the analgesic efficacy of the ITPB at the retro-SCTL space in patients undergoing major open hepatectomy surgery.
- Conditions
- Hepatectomy, Intertransverse Process Block, Quality of Recovery (QoR-15)
- Trial name
- ITPB QoR (NCT06957041)
- Testing
- Intertransverse process block
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
1. Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver, representing the third leading cause of cancer-related death worldwide. 2.
- Trial name
- NCT02109146
- Testing
- Prophylactic Transcatheter Arterial Chemoembolization, Observation
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC)
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative…
- Trial name
- NCT04639180
- Testing
- Camrelizumab, Rivoceranib (Apatinib)
- Where
- 6 sites in China
- Volunteers
- 687 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Liver Cancer, Liver Neoplasms
Nursing Fro Laparoscopic vs. Open Hepatectomy
This study was divided into laparoscopic hepatectomy (observation group) and laparoscopic hepatectomy (control group).Compared two groups of age, sex, body mass index (BMI), tumor diameter, number of tumors (single/multiple)…
- Trial name
- NCT03585166
- Testing
- lpaparoscopic hepatectomy, open hepatectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hemorrhage
PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection…
- Trial name
- NCT02204930
- Testing
- PeproStat
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Haemostatix Ltd
Hepatocellular Carcinoma, Adjuvant Therapy
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative…
- Trial name
- NCT04981665
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Liver Resection, Colorectal Carcinoma Liver Metastases
Safety of HRX215 in Patients After Minor and Major Liver Resection
The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1.
- Trial name
- NCT06638502
- Testing
- HRX215 capsules
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 80 people
- Sponsor
- HepaRegeniX GmbH